| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Laboratory of Biology and Therapy of Metastasis [D. B., P. P., L. M., A. G., G. T., R. G.] and Laboratory of Molecular Pharmacology [S. M.], Department of Oncology, Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
 |
ABSTRACT |
|---|
 Top ABSTRACT IntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
|
Introduction |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
The expression of VEGF in ovarian carcinoma has been associated with tumor growth and invasion (5) . High levels of VEGF have been found in serum or plasma and ascites of ovarian cancer patients (6) . A correlation between ascites volume and VEGF levels has been reported in several experimental models (2) . Inhibitors of VEGF activity reduced the formation of malignant ascites in human ovarian carcinoma xenograft models (7) .
MMPs are zinc-dependent endopeptidases with a similar domain structure secreted in a latent (pro) form and activated by proteolytic removal of the NH2-terminal propeptide. MMPs promote cancer progression by boosting cancer cell growth, migration and invasion, and metastasis and angiogenesis. During these processes, proteolytic enzymes act at different levels. They degrade basement membranes allowing cancer cell invasion and exposing cryptic sites within matrix molecules (8) , increase the bioavailability of growth factors and cytokines (9) , and regulate the function of bioactive molecules by proteolytic processing (10) . The role of MMP2 and MMP9 has been particularly highlighted in the last few years using different in vivo and in vitro experimental models (11) .
Ovarian cancer cells express MMP2 and MMP9 (12) , and their increased expression is associated with their invasive and metastatic potential (13) . We and others have reported that MMP2 and MMP9 are expressed in ascites and plasma of ovarian cancer patients (6) . Furthermore, experimental studies have shown that animals bearing ovarian carcinoma xenografts in the peritoneal cavity and treated with MMP inhibitors formed fewer ascites and survived longer (14) . A recent study showed that stromal MMP9 contributes to the malignant behavior of ovarian cancers by promoting neovessel sprouting and tumor growth (11) . In the same study, VEGF was more expressed in ovarian tumors growing in nude mice with wild-type MMP9 than in mice that lacked an intact MMP9 gene (11) . These findings suggest an interplay between VEGF and MMP9. However, the direct relationship between MMPs in general and specifically MMP9 activation and VEGF levels in the progression of ovarian carcinomas, particularly in ascites formation, still needs to be demonstrated.
We investigated a functional link between gelatinase activation, VEGF release, and ascites formation in human ovarian carcinoma models. Two xenografts of human ovarian carcinoma (HOC22 and HOC8) produced ascites after transplantation in the peritoneal cavity of nude mice. The ascites volume was directly proportional to the activation status of MMP9 and the VEGF levels in ascites. We also found that activated MMP9, and to a lesser extent MMP2, increased the release of soluble VEGF by the human ovarian carcinoma cell lines SKOV3 and OVCAR3 in vitro. Finally, the release of VEGF was inhibited by the metalloproteinase inhibitor BB-94 both in vivo and in vitro.
|
Materials and Methods |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
Cell Lines and Xenografts.
HOC22 and HOC8 xenografts, established and maintained i.p. in nude mice as described previously (15)
, grew in the peritoneal cavity, producing ascites. As these xenografts do not grow in tissue culture, the human ovarian carcinoma cell lines SKOV3 and OVCAR3 were used for in vitro studies. Both the cell lines were obtained from the Division of Cancer Treatment, Tumor Repository (National Cancer Institute). Cells were cultured in RPMI 1640 (Life Technologies, Inc., Europe, Paisley, Scotland) supplemented with 10% FCS and 5 mM glutamine. HUVECs were isolated from umbilical cord veins and grown as described previously (16)
.
Reagents and Drugs.
Batimastat (BB-94) was provided by British Biotech Ltd. (Oxford, England). For in vivo experiments, BB-94 was formulated in 2.5% ethanol, 2.5% PEG400, and 1% methylcellulose and further dissolved in 5% glucose. For in vitro experiments, it was dissolved in DMSO (stock solution 5 x 10-3 M) and diluted with medium before the assay.
SU5416 was provided by SUGEN (San Francisco, CA). The compound was dissolved in DMSO (stock solution 4 x 10-2 M) and diluted with medium before use. Human recombinant MMP2 and MMP9 were purchased from R&D Systems (Minneapolis, MN).
Preparation of Conditioned Medium.
Tumor cells were seeded in duplicate in 24-well plates and growth in culture medium for 48 h. Subconfluent cultures were then washed three times with saline and incubated for different times in serum-free medium. Conditioned medium was collected, centrifuged, and kept frozen at -80°C until analysis for VEGF content.
i.p. Tumor Growth.
Nude mice were inoculated i.p. with 10 x 106 HOC22 and HOC8 cells (day 0). At different times after injection, mice were euthanized by carbon dioxide inhalation. Ascites was harvested and centrifuged, and the volume of fluid and number of cells in the pellet (representative of tumor burden) were recorded for each mouse. Ascitic fluid was stored at -80°C until analysis. Where indicated, BB-94 at the concentration of 60 mg/kg and the corresponding vehicle were administered i.p. every 7 days for three times starting 4 days after tumor cell inoculation. Three days after the last treatment, ascites were harvested and processed as described above.
Analysis of VEGF in Ascites and Conditioned Medium.
VEGF was measured by ELISA (Quantikine; R&D Systems), according to the manufacturer’s instructions. This assay specifically recognizes human VEGF121 and VEGF165. The sensitivity of the assay was 9 pg/ml. Each sample was analyzed in duplicate. Western blotting was performed using a polyclonal antibody (Santa Cruz Biotechnology, Inc.) raised against a peptide mapping at the NH2 terminus of VEGF of human origin and reacting with the 121, 165, and 189 amino acid splice variants of VEGF. Analysis of VEGF expression in tumor cells: 1 µg of total RNA, purified from ovarian tumor cells harvested from the peritoneal cavity of nude mice, was retro-transcribed in 20-µl reaction mixture using M-MuLV reverse transcriptase and random hexamer primers accordingly to manufacturer’s instructions (RT-PCR core Kit; Applied Biosystems, Warrington, United Kingdom). Aliquots (2 µl) of RT-PCR products were subsequently used for PCR amplifications carried out in PTC-200 thermal cycler (MJ Research; Celbio, Milan, Italy). To amplify the different VEGF isoforms, primer sequences and amplification conditions were selected on data reported previously (17)
. As an internal reference, the housekeeping gene ß-actin was amplified with the set of primers published previously (18)
.
Analysis of MMP Expression in Ascites.
Zymography was done using SDS-polyacrylamide (10%) gels copolymerized with 1 mg/ml gelatin (Sigma Chemical Co.). The sample volumes were adjusted according to the protein concentration. Conditioned medium of WM983A melanoma cells and NIH3T3 fibroblasts activated or not with p-aminophenylmercuricacetate were used as reference standard, respectively, for human and murine MMP-9 and MMP-2. Western blotting was performed using monoclonal antibodies (Immunological Sciences, Rome, Italy) recognizing pro- and active forms of MMP9 and MMP2.
Cell Migration.
Endothelial cell migration was evaluated using Boyden chambers and 8-µm pore size, gelatin-coated polycarbonate Nucleopore filters, as described (19)
. Conditioned medium of SKOV3 treated or not with MMP9 was used as the chemoattractant in the bottom compartment of the chamber. HUVEC 1 x 106/ml were added to the top compartment. SU5416 was incubated with the cells for 30 min before and throughout the assay. After a 4-h incubation at 37°C, filters were stained with Diff Quick (Merz-Dade, Dudingen, Switzerland), and the number of migrated cells in 10 high-power fields was counted.
Statistical Analysis.
Statistical significance was determined by the two-tailed Mann-Whitney U test. The limit of statistical significance was P 
0.05.
|
Results |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
.
|
. Accordingly, the different isoforms of VEGF were detectable in the ascitic fluid, and their expression increased with time of tumor progression (Fig. 1d)
. The amount of MMP2 and MMP9 released in ascites, measured in zymography, also correlated with tumor burden and ascites volume (Fig. 1e)
. Both human and murine proforms of MMP2 and MMP9 were detected in ascites of mice bearing HOC22. The activated form of MMP9 was detectable 24 and 34 days after tumor injection when VEGF levels were high, but the activated form of MMP2 was never detectable. MMP and VEGF levels and the ascites reached a plateau at the same time, 24 days after tumor transplant. Similar results were obtained with the other xenograft model HOC8 (data not shown).
BB-94 Inhibits the Release of VEGF in Ascites and the Formation of Ascitic Fluid in Ovarian Carcinoma Xenografts.
We had shown previously that the treatment of nude mice bearing HOC22 or HOC8 with BB-94 delayed tumor growth and increased mice survival (14)
. Fig. 2
shows that treatment of HOC22-bearing mice with BB-94 reduced the ascites (median 5 and 3 ml in vehicle-treated and BB-94-treated mice, respectively) but not the tumor burden (median 44 x 106 and 46 x 106 cells; Fig. 2, a and b
). Despite the similar tumor burden, VEGF levels were significantly lower in the ascites of BB-94-treated mice (median 1936.8 pg/ml) than in mice treated with vehicle (median 14036.7 pg/ml; Fig. 2c
). Therefore, the decrease in VEGF levels and ascitic volume was not caused by a reduction in tumor burden but might conceivably have been caused by inhibition of protease activity.
|
. MMP2 had less effect on VEGF release, increasing it by 20–40% after 24 h (Fig. 3a)
. The effect of MMP9 treatment on VEGF release was dose dependent. (Fig. 3b)
.
|
. BB-94 also blocked MMP2-stimulated release of VEGF by SKOV3 cells (data not shown). Similar results were obtained with another ovarian carcinoma cell line, OVCAR-3, in which exogenous activated MMP9 and MMP2 increased the release of VEGF by 250 and 80% respectively. In this case too, the effect was dose and time dependent and inhibited by BB-94 (data not shown).
Conditioned Medium-induced Endothelial Cell Migration Is Increased by MMP9 Treatment.
We next investigated whether the increased release of VEGF induced by MMP9 in ovarian carcinoma cells resulted in a true increment of the angiogenic potential of the tumor cells by testing the ability of SKOV3 conditioned medium to stimulate the migration of endothelial cells. Conditioned medium from SKOV3 treated with MMP9 induced greater endothelial cell migration than its untreated counterpart (Fig. 4a)
. SU5416, an inhibitor of VEGF-R2 (KDR/flk), was used to prove the specificity of the effect. SU5416 caused 70–90% inhibition of cell migration in response to MMP9-treated SKOV3 conditioned medium, proving that the effect was indeed mediated by VEGF (Fig. 4b)
. As expected, SU5416 selectively inhibited HUVEC motility induced by VEGF but not that induced by fibronectin. These findings indicate that VEGF released after MMP9 treatment was biologically active. Recombinant MMP9 used as chemoattractant in a range of concentration greater or equal to that contained in SKOV3 conditioned medium (between 10 and 1.25 ng/ml) did not stimulate HUVEC migration (data not shown), thus excluding a direct role of MMP in the induction of migration.
|
|
Discussion |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
A functional interaction between VEGF and MMPs has been observed in other tumor models. Specifically, MMP9 increased the bioavailability of VEGF in the K14-HPV16 skin cancer model (21) and RIP1-Tag2 insulinoma model (9) , although it is not known exactly how. In ovarian cancer, the MMP-VEGF relationship is indicated by several observations. Huang et al. (11) , using in vivo models of ovarian carcinoma, found an important role for macrophage- derived MMP9 in angiogenesis and ovarian tumor growth; ovarian tumors from mice with a homozygous null mutation in the MMP9 gene had lower microvessel density, and tumor cells expressed lower levels of VEGF than tumors from mice wild type for the MMP9 gene. However, they did not describe direct functional connection between MMP9 activation, VEGF release, and ascites formation.
Our finding that activated MMP9 is associated with high VEGF bioavailability in cultured and transplanted ovarian carcinoma strongly supports a direct role of MMP in ascites formation. Activated MMP9 accumulated in the peritoneal cavity of mice 24 and 34 days after i.p. injection of HOC22 or HOC8 ovarian tumor cells, when large amounts of VEGF were present in ascites. Zymographic analysis enabled us to distinguish between human MMP9 secreted by the tumor cells xenografted in nude mice and murine MMP9 derived from host cells. In line with recent data showing that stromal MMP9 promotes angiogenesis and growth of ovarian cancer xenografted in nude mice (11) , we detected high levels of host-derived, murine MMP9 in ascites, increasing with the ascites formation. However, as human MMP9 was also secreted in the ascitic fluid, it is possible that MMP9 from both origins influence VEGF release and ascites formation. The relative roles of host- and tumor-derived MMP9 need to be defined.
Only MMP2 proform was present in ascites, its activated form never being detectable, suggesting a secondary role for this MMP in VEGF release in vivo. This was confirmed in vitro where exogenous MMP2 was less effective in inducing VEGF release than MMP9. A fundamental role of MMP9 in VEGF release has been reported previously in the angiogenic switch of the RIP1-Tag2 insulinoma model (9) .
SKOV3 cells constitutively release VEGF, MMP9, and MMP2 in culture medium in a time-dependent fashion (data not shown). These findings are in favor of a role for endogenous MMPs in the spontaneous release of VEGF.
Zymography revealed a second band in the Mr 72,000 range whose expression increased with time after tumor transplantation. In Western blot analysis, this band was specifically recognized by an anti-MMP2 but not by an anti-MMP9 antibody (data not shown). Moreover: (a) it is a calcium-dependent protease, because the depletion of CaCl2 in zymography completely inhibits the digestion band; and (b) it is probably of murine origin, because it is not expressed in ascites from ovarian carcinoma patients and in conditioned medium of human cancer cells in vitro but only in cells of murine origin (data not shown). Additional studies are necessary to characterize this molecule and its possible role in the release of growth factors.
VEGF is one of the most potent angiogenic factors. We found that conditioned medium from MMP9-treated tumor cells induced endothelial cell migration. Their migration was blocked by SU5416, a VEGF tyrosine kinase receptor inhibitor. This confirms the activity of VEGF released by MMP9. SU5416 is considered a potent selective inhibitor of the tyrosine kinase activity of VEGF receptor-2, but it inhibits the phosphorylation of other tyrosine kinase receptors too (22) . Therefore, it is possible that besides VEGF, activated MMP9 causes the release of other angiogenic/growth factors whose activity is also inhibited by SU5416.
Different MMPs modify the bioavailability of angiogenic factors sequestered in the ECM (23) and process a variety of bioactive molecules, which are regulators of vascular growth or function, including fibroblast growth factor receptor type 1 (24) , tumor necrosis factor (25) , and heparin-binding epidermal growth factor (26) . The role of gelatinases in VEGF release was confirmed by our finding that treatment of mice bearing ascites with the MMP inhibitor BB-94 lowered VEGF levels, with a reduction in ascitic volume. At the dose and schedule used in our studies, BB-94 did not affect tumor burden. We conclude that the decrease in VEGF release and, as a consequence, in ascites volume was exclusively caused by inhibition of gelatinolytic activity by BB-94. Accordingly, in vitro, BB-94 reduced the amount of VEGF released in SKOV3 conditioned medium at a concentration that did not affect tumor cell proliferation and survival, confirming that MMPs are indeed required. BB94 is a broad spectrum inhibitor of proteases, so we cannot exclude that other MMPs, beside MMP9, are involved in inducing VEGF release.
There are several possible mechanisms of action of MMPs: (a) directly stimulating VEGF release from tumor cells; (b) activating other factors involved in VEGF release; and (c) mobilizing VEGF from the extracellular compartments. The fact that also the larger isoforms of VEGF are detectable in ascites suggests an effect on the bioavailability of VEGF bound to the ECM. Additional studies are necessary to clarify this phenomenon.
In conclusion, our results provide direct evidence that MMPs, mainly MMP9, contribute to the formation of ascites through the release of VEGF. Targeting MMP9 in tumor cells or host-derived cells could offer a way to control tumor progression and ascites in human ovarian carcinoma.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and Fondazione Italiana per la Ricerca sul Cancro (FIRC) and MIUR-Oncologia (to R. G.). D. B. is the recipient of a fellowship from the Consiglio Nazionale delle Ricerche (CNR) (bando N.201.17.3). 
2 To whom requests for reprints should be addressed, at Laboratory of Biology and Therapy of Metastasis, Mario Negri Institute for Pharmacological Research, via Gavazzeni 11, 24125 Bergamo, Italy. Phone: 39 035 319888; Fax: 39 035 319331; E-mail: Belotti{at}marionegri.it
3 The abbreviations used are: VEGF, vascular endothelial growth factor; HUVEC, human umbilical vein endothelial cell; MMP, matrix metalloproteinase; RT-PCR, reverse transcription-PCR; ECM, extracellular matrix.
Received 3/21/03. Revised 6/ 9/03. Accepted 7/ 9/03.
|
REFERENCES |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  S. MacLauchlan, E. A. Skokos, A. Agah, J. Zeng, W. Tian, J. M. Davidson, P. Bornstein, and T. R. Kyriakides Enhanced Angiogenesis and Reduced Contraction in Thrombospondin-2-null Wounds Is Associated With Increased Levels of Matrix Metalloproteinases-2 and -9, and Soluble VEGF J. Histochem. Cytochem., April 1, 2009; 57(4): 301 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. MacLauchlan, E. A. Skokos, N. Meznarich, D. H. Zhu, S. Raoof, J. M. Shipley, R. M. Senior, P. Bornstein, and T. R. Kyriakides Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9 J. Leukoc. Biol., April 1, 2009; 85(4): 617 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. de Nooijer, I. Bot, J.H. von der Thusen, M.A. Leeuwenburgh, H.S. Overkleeft, A.O. Kraaijeveld, R. Dorland, P.J. van Santbrink, S.H. van Heiningen, M.M. Westra, et al. Leukocyte Cathepsin S Is a Potent Regulator of Both Cell and Matrix Turnover in Advanced Atherosclerosis Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 188 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, M. Bukulin, E. Kojro, A. Roth, V. V. Metz, F. Fahrenholz, P. P. Nawroth, A. Bierhaus, and R. Postina Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases J. Biol. Chem., December 19, 2008; 283(51): 35507 - 35516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yagi, F. Yotsumoto, and S. Miyamoto Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition Mol. Cancer Ther., October 1, 2008; 7(10): 3441 - 3451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Stathopoulos, C. Moschos, H. Loutrari, A. Kollintza, I. Psallidas, S. Karabela, S. Magkouta, Z. Zhou, S. A. Papiris, C. Roussos, et al. Zoledronic Acid Is Effective against Experimental Malignant Pleural Effusion Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 50 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Belotti, C. Calcagno, A. Garofalo, D. Caronia, E. Riccardi, R. Giavazzi, and G. Taraboletti Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion Mol. Cancer Res., April 1, 2008; 6(4): 525 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zou, R. Yang, J. Chai, and G. Pei Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis FASEB J, February 1, 2008; 22(2): 355 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Said, M. J. Socha, J. J. Olearczyk, A. A. Elmarakby, J. D. Imig, and K. Motamed Normalization of the Ovarian Cancer Microenvironment by SPARC Mol. Cancer Res., October 1, 2007; 5(10): 1015 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Robinson-Smith, I. Isaacsohn, C. A. Mercer, M. Zhou, N. Van Rooijen, N. Husseinzadeh, M. M. McFarland-Mancini, and A. F. Drew Macrophages Mediate Inflammation-Enhanced Metastasis of Ovarian Tumors in Mice Cancer Res., June 15, 2007; 67(12): 5708 - 5716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Sharp, C. Prodromou, K. Boxall, M. V. Powers, J. L. Holmes, G. Box, T. P. Matthews, K.-M. J. Cheung, A. Kalusa, K. James, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues Mol. Cancer Ther., April 1, 2007; 6(4): 1198 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Moore, X.-D. Shen, F. Gao, R. W. Busuttil, and A. J. Coito Fibronectin-{alpha}4{beta}1 Integrin Interactions Regulate Metalloproteinase-9 Expression in Steatotic Liver Ischemia and Reperfusion Injury Am. J. Pathol., February 1, 2007; 170(2): 567 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W.T. Cheung, P. C.K. Leung, and A. S.T. Wong Gonadotropin-Releasing Hormone Promotes Ovarian Cancer Cell Invasiveness through c-Jun NH2-Terminal Kinase-Mediated Activation of Matrix Metalloproteinase (MMP)-2 and MMP-9. Cancer Res., November 15, 2006; 66(22): 10902 - 10910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V. Yang, A. K. Sood, M. Chen, Y. Li, T. D. Eubank, C. B. Marsh, S. Jewell, N. A. Flavahan, C. Morrison, P.-E. Yeh, et al. Norepinephrine Up-regulates the Expression of Vascular Endothelial Growth Factor, Matrix Metalloproteinase (MMP)-2, and MMP-9 in Nasopharyngeal Carcinoma Tumor Cells Cancer Res., November 1, 2006; 66(21): 10357 - 10364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-q. Wang, Y. Smicun, N. Calluzzo, and D. A. Fishman Inhibition of Matrilysin Expression by Antisense or RNA Interference Decreases Lysophosphatidic Acid-Induced Epithelial Ovarian Cancer Invasion Mol. Cancer Res., November 1, 2006; 4(11): 831 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Godzich, M. Hodnett, J. A. Frank, G. Su, M. Pespeni, A. Angel, M. B. Howard, M. A. Matthay, and J. F. Pittet Activation of the stress protein response prevents the development of pulmonary edema by inhibiting VEGF cell signaling in a model of lung ischemia-reperfusion injury in rats FASEB J, July 1, 2006; 20(9): 1519 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hossein Pourgholami, Z. Yan Cai, Y. Lu, L. Wang, and D. Lawson Morris Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice. Clin. Cancer Res., March 15, 2006; 12(6): 1928 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kurban, V. Hudon, E. Duplan, M. Ohh, and A. Pause Characterization of a von Hippel Lindau Pathway Involved in Extracellular Matrix Remodeling, Cell Invasion, and Angiogenesis Cancer Res., February 1, 2006; 66(3): 1313 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. de Nooijer, C.J.N. Verkleij, J.H. von der Thusen, J.W. Jukema, E.E. van der Wall, Th. J.C. van Berkel, A.H. Baker, and E.A.L. Biessen Lesional Overexpression of Matrix Metalloproteinase-9 Promotes Intraplaque Hemorrhage in Advanced Lesions But Not at Earlier Stages of Atherogenesis Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Said and K. Motamed Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis Am. J. Pathol., December 1, 2005; 167(6): 1739 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kaliski, L. Maggiorella, K. A. Cengel, D. Mathe, V. Rouffiac, P. Opolon, N. Lassau, J. Bourhis, and E. Deutsch Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion Mol. Cancer Ther., November 1, 2005; 4(11): 1717 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Arora, J. Kaur, C. Sharma, M. Mathur, S. Bahadur, N. K. Shukla, S. V.S. Deo, and R. Ralhan Stromelysin 3, Ets-1, and Vascular Endothelial Growth Factor Expression in Oral Precancerous and Cancerous Lesions: Correlation with Microvessel Density, Progression, and Prognosis Clin. Cancer Res., March 15, 2005; 11(6): 2272 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Pellikainen, K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V.-M. Kosma Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis Clin. Cancer Res., November 15, 2004; 10(22): 7621 - 7628. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
), and volume of ascites (
), were evaluated at different times after tumor transplant. VEGF in ascitic fluids were evaluated at different times after tumor transplant by ELISA (b) and Western blot (c). Results in a and b are the mean ± SD of three mice per group. d, RT-PCR showing the expression of the different VEGF isoforms in cells harvested from the peritoneal cavity of nude mice at different times after tumor transplant (two mice/time). e, zymography showing a representative example of MMP expression and activation in ascites.
), and fibronectin (20 µg/ml, 
) were used as the attractants. Results are the number of migrated cells (means and SD of at least three values from one experiment representative of two). *P < 0.05 compared with control.